GlobalData on MSN5d
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B
These pathogens are identified as primary causes of gastrointestinal illnesses by the Infectious Diseases Society of America.
Yahoo Finance6d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (Bacterial & Viral) that covers Campylobacter, Salmonella, Shiga-like toxin-producing Escherichia coli (STEC ...
EuropaWire5d
QIAGEN Gains FDA Approval for New QIAstat-Dx Gastrointestinal Panel 2 Mini B, Expanding Syndromic Testing Options
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
DutchNews.nl6d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN’s growing U.S. menu for syndromic testing of gastrointestinal ...
Yahoo Finance6d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands, March 06, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared ...